WO1997026863A1 - Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen - Google Patents
Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen Download PDFInfo
- Publication number
- WO1997026863A1 WO1997026863A1 PCT/EP1997/000230 EP9700230W WO9726863A1 WO 1997026863 A1 WO1997026863 A1 WO 1997026863A1 EP 9700230 W EP9700230 W EP 9700230W WO 9726863 A1 WO9726863 A1 WO 9726863A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pulmonary surfactant
- proteins
- organic solution
- suspension
- spray drying
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the invention relates to a method for producing pulverulent pulmonary surfactant preparations.
- the lungs of all vertebrates contain a mixture of substances called "pulmonary surfactant". It shows surface-active properties and lowers the surface tension in the alveolar area of the lungs so that a collapse of the final airway areas during exhalation is avoided.
- This mixture of substances regulates the surface tension dynamically, so that the collapse of the small alveoli in favor of the larger alveoli, which is to be expected according to Laplacian law, is avoided by adapting the surface tension accordingly.
- the result is a well-balanced, histologically and physiologically stable structure of the lungs.
- Lung surfactant is secreted by type II alveolar pneumocytes in the form of lamellar bodies. These are compact units made of phospholipid double layers (bilayer) with a high proportion of dipalmitoylphosphatidylcholine (DPPC) and phosphatidylglycerol (PG). Lung surfactant contains proteins which are designated as SP-A, SP-B and SP-C as further essential components. SP-A is a high molecular weight glycoprotein that plays a crucial role in regulating secretion.
- the hydrophobic proteins SP-C and, to a lesser extent, SP-B assume the role of "thermodynamic catalysts" in the formation of the monomolecular surface film (the surfactant in the narrower sense).
- the presence of these proteins accelerates the spreading kinetics enormously. Only then is it possible to adapt the surfactant composition to the respective surface tension requirements without delay.
- IRDS Infant Respiratory Distress Syndrome
- IRDS is the main cause of death in premature babies. It has been proven for many years to treat IRDS by introducing pulmonary surfactant preparations into the lungs of the affected children. From pilot studies it is known that lung surfactant preparations are also clinically effective in ARDS (Adult Respiratory Distress Syndrome) including ALI (Acute Lung Injury).
- Pulmonary surfactant preparations can be obtained from animal lungs in a complex extraction and centrifugation process (pulmonary lavage) or can be composed of individual components.
- WO 92/06703 describes the preparation of synthetic pulmonary surfactant preparations by evaporation of a chloroform solution containing phospholipids, such as dipalmitoylphosphatidylcholine (DPPC) and dioleylphosphatidylethanolamine (DOPE), and cholesterol on a rotary evaporator to form a thin film, if desired together with suitable proteins, in a buffer together with suitable proteins is resuspended.
- DPPC dipalmitoylphosphatidylcholine
- DOPE dioleylphosphatidylethanolamine
- WO 91/00871 From WO 91/00871 it is known to concentrate an organic solution of a pulmonary surfactant preparation which contains a genetically engineered pulmonary surfactant protein, to rehydrate it with a buffer and then to lyophilize it.
- the lyophilizate obtained has the disadvantage that it has to be rehydrated prior to administration 15 minutes at 37 * C, which is perceived by the user as very cumbersome and error prone.
- EP 0119056 specifies a process for the preparation of a pulmonary surfactant preparation in which all the constituents are dissolved in an organic solvent, the solution obtained is evaporated to dryness under reduced pressure, and the residue obtained in an aqueous medium at elevated temperature over a prolonged period Period is resuspended and the suspension obtained is subjected to freeze drying. This process is also technically very complex.
- DE 3229179 discloses a method for producing a protein-free pulmonary surfactant preparation, in which the constituents are dissolved in glacial acetic acid and the solution obtained is freeze-dried.
- the disadvantage of this method is the use of glacial acetic acid, because this requires extensive safety measures.
- EP 0655237 proposes to prepare pharmaceutical preparations which are to be administered by inhalation in the form of a suspension aerosol by spray drying from ethanol / water mixtures. This method is described, inter alia, as being suitable for compositions containing hydrophilic proteins, such as B. ecatiban acetate, human insulin and buserelin acetate. Description of the invention
- the object on which the present invention is based is to provide a method for producing protein-containing pulverulent pulmonary surfactant preparations containing hydrophobic pulmonary surfactant proteins which is technically as inexpensive as possible and which leads to an advantageously usable storage-stable product.
- This process gives a product which is stable in storage for a long time and can be resuspended before use without any particular effort.
- a particular advantage of the powder obtained is its small particle size (1 to 5 ⁇ m), which allows inhalation administration. This aspect is of particular importance when using lung surfactant preparations as tractors for drugs that can be administered via the lungs.
- lung surfactant protein SP-C is aggregated very quickly above -20 ⁇ C and thus inactivated.
- this protein survives the spray drying process according to the invention without noticeable decomposition and is then present as a loose powder which can be stored at room temperature.
- the invention therefore relates to a process which is characterized in that an organic solution or suspension comprising hydrophobic pulmonary surfactant proteins and, if desired, further components are subjected to spray drying.
- Suitable hydrophobic pulmonary surfactant proteins are those of natural origin as well as synthetically, including genetically engineered, proteins, in particular SP-B and SP-C, and mixtures thereof. Synthetic proteins should also be understood to mean those proteins whose amino acid sequence deviates more or less strongly from the amino acid sequence of naturally occurring pulmonary surfactant proteins, including those synthetic proteins which have an amino acid sequence which is completely independent of their pulmonary surfactant property, as they do for example in EP 0593094 and EP 92/22315 are described. These proteins can be isolated, synthesized and purified by known methods.
- Suitable solvents for the preparation of an organic solution or suspension are, according to the invention, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, butanols, chlorinated hydrocarbons such as dichloromethane, chloroform etc., acetone, ether, hydrocarbons, benzene, toluene and their mixtures, which may also contain water, provided that it is miscible with water.
- the maximum water content is 25% by weight.
- a water content of 5 to 15% by weight is preferred. It is easy for a person skilled in the art to select the solvents or solvent mixtures which are most suitable for the surfactant mixtures to be dried, on the basis of his specialist knowledge in the field of spray drying and, if necessary, by means of conventional tests.
- the pulmonary surfactant preparations contain the usual substances, such as in particular phospholipids, carboxylic acids and buffer substances, as further constituents.
- the solution can be filtered through a sterile filter before spray drying begins.
- Spray drying is carried out in a manner known per se. A detailed description of this technique can be found in K. Masters, Spray Drying Handbook, 5th Ed. 1991, and J. Broadhead, S.K. Edmond Ronan, C.T. Rhodes, The Spray Drying of Phanmaceuticals, Drug Dev. Ind. Pharm. 18, 1169 (1992).
- the principle of spray drying is to split a solution or suspension of the product to be dried into fine droplets and to dry it with a hot gas stream.
- the solid fraction remaining after evaporation of the solvent is separated from the gas stream by means of a cyclone and / or by a filter unit and collected.
- alcohols and chlorinated hydrocarbons in particular methanol, ethanol, 2-propanol and chloroform and mixtures thereof, if appropriate with a small amount of water (up to a maximum of 25% by weight) as solvents.
- Air and nitrogen are particularly suitable as drying gases.
- the gas inlet temperature is kept at 40 to 80 ° C., preferably 50 to 70 ° C., by appropriate control of the spraying power and / or the amount of gas.
- a solution of surfactant obtained from bovine lungs (obtained by extraction and purification steps, as described, for example, in EP 406732) in chloroform / methanol is spray-dried under the following conditions: laboratory spray dryer Büchi B 191, drying gas nitrogen, inlet temperature 80 ° C., outlet temperature 50-52 ° C. A fine, yellowish powder is obtained.
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97902186A EP0877602B1 (de) | 1996-01-24 | 1997-01-18 | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
CA002244767A CA2244767C (en) | 1996-01-24 | 1997-01-18 | Process for the production of powdered pulmonary surfactant preparations |
DE59706180T DE59706180D1 (de) | 1996-01-24 | 1997-01-18 | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
IL12543997A IL125439A (en) | 1996-01-24 | 1997-01-18 | Process for the production of powdered pulmonary surfactant preparations |
AT97902186T ATE212220T1 (de) | 1996-01-24 | 1997-01-18 | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
AU15930/97A AU714998B2 (en) | 1996-01-24 | 1997-01-18 | Process for producing pulverulent pulmonary surfactant preparations |
JP52650697A JP3725166B2 (ja) | 1996-01-24 | 1997-01-18 | 粉末状肺サーファクタント製剤の製造方法 |
UA98084525A UA59358C2 (uk) | 1996-01-24 | 1997-01-18 | Спосіб приготування порошкоподібного пульмонологічного порошкоподібного препарату та препарат, одержаний в такий спосіб |
EA199800649A EA001382B1 (ru) | 1996-01-24 | 1997-01-18 | Способ получения порошковых препаратов лёгочного поверхностно-активного вещества |
US09/117,142 US6315983B1 (en) | 1996-01-24 | 1997-01-18 | Process for the production of powdered pulmonary surfactant preparations |
DK97902186T DK0877602T3 (da) | 1996-01-24 | 1997-01-18 | Fremgangsmåde til fremstilling af pulverformede lungesurfactant-præparater |
BR9707299A BR9707299A (pt) | 1996-01-24 | 1997-01-18 | Processo para a fabricação de preparações de tensoativo pulmonar em forma de pó |
HU9900954A HU224988B1 (en) | 1996-01-24 | 1997-01-18 | Process for the production of powdered pulmonary surfactant preparations |
PL97328194A PL187293B1 (pl) | 1996-01-24 | 1997-01-18 | Sposób wytwarzania sproszkowanych kompozycji surfaktantu płuc, sproszkowana kompozycja surfaktantu płuc i zastosowanie sproszkowanej kompozycji |
HK99105345A HK1020016A1 (en) | 1996-01-24 | 1999-11-18 | Process for the production of powdered pulmonary surfactant preparations. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19602332.7 | 1996-01-24 | ||
DE19602332A DE19602332A1 (de) | 1996-01-24 | 1996-01-24 | Verfahren zur Herstellung von pulverförmigen Lungensurfactant-Zubereitungen |
EP96103442.8 | 1996-03-06 | ||
EP96103442 | 1996-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997026863A1 true WO1997026863A1 (de) | 1997-07-31 |
Family
ID=26022286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/000230 WO1997026863A1 (de) | 1996-01-24 | 1997-01-18 | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
Country Status (15)
Country | Link |
---|---|
US (1) | US6315983B1 (de) |
EP (1) | EP0877602B1 (de) |
JP (1) | JP3725166B2 (de) |
KR (1) | KR100449789B1 (de) |
AT (1) | ATE212220T1 (de) |
CA (1) | CA2244767C (de) |
CY (1) | CY2366B1 (de) |
CZ (1) | CZ292186B6 (de) |
DE (1) | DE59706180D1 (de) |
DK (1) | DK0877602T3 (de) |
ES (1) | ES2171883T3 (de) |
PT (1) | PT877602E (de) |
TR (1) | TR199801408T2 (de) |
UA (1) | UA59358C2 (de) |
WO (1) | WO1997026863A1 (de) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0971698A1 (de) * | 1996-12-31 | 2000-01-19 | Inhale Therapeutic Systems | Aerolisiertes hydrophobisches medikament |
WO2000010541A1 (en) * | 1998-08-25 | 2000-03-02 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
WO2000027360A1 (en) * | 1998-11-10 | 2000-05-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Treatment set containing lungsurfactant compositions |
WO2000076535A1 (en) * | 1999-06-11 | 2000-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
WO2001013892A2 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Large porous particles by spray-drying |
DE19957898A1 (de) * | 1999-12-01 | 2001-06-07 | Byk Gulden Lomberg Chem Fab | Neue Verwendung von Lungensurfactant |
WO2003077891A1 (fr) * | 2002-03-18 | 2003-09-25 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicales en poudre pour inhalation et procede de production de celles-ci |
US6982075B2 (en) | 2001-10-11 | 2006-01-03 | Altana Pharma Ag | Use of pulmonary surfactant |
US7053176B1 (en) | 1999-09-16 | 2006-05-30 | Altana Pharma Ag | Combination of C1-INH and lung surfactant for the treatment of respiratory disorders |
EP1767195A2 (de) * | 1998-08-25 | 2007-03-28 | Advanced Inhalation Research, Inc. | Stabile sprühgetrocknete Proteinformulierungen |
US7790145B2 (en) | 1997-09-29 | 2010-09-07 | Novartis Ag | Respiratory dispersion for metered dose inhalers |
US8168223B1 (en) * | 1997-09-29 | 2012-05-01 | Novartis Pharma Ag | Engineered particles and methods of use |
US8236750B2 (en) | 2004-08-06 | 2012-08-07 | Nycomed Gmbh | Composition comprising a pulmonary surfactant and a TNF-derived peptide |
US8337815B2 (en) | 2004-12-23 | 2012-12-25 | Discovery Laboratories, Inc. | Pulmonary surfactant formulations |
US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
US9289388B2 (en) | 2008-12-10 | 2016-03-22 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
US9421166B2 (en) | 2001-12-19 | 2016-08-23 | Novartis Ag | Pulmonary delivery of aminoglycoside |
US9693955B2 (en) | 2010-08-23 | 2017-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Humidified particles comprising a therapeutically active substance |
WO2017223502A1 (en) * | 2016-06-24 | 2017-12-28 | Civitas Therapeutics, Inc. | Surfactant formulations for inhalation |
EP1280520B2 (de) † | 2000-05-10 | 2018-03-21 | Novartis AG | Pulver auf basis von phospholipiden zur wirkstoffverabreichung |
EP3727418A4 (de) * | 2017-12-21 | 2021-10-27 | Civitas Therapeutics, Inc. | Tensidformulierungen zur inhalation |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
WO2003043603A1 (en) * | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US20030170223A1 (en) * | 2002-02-01 | 2003-09-11 | Board Of Trustees Of Michigan State University | Pulmonary vasodilator surfactant compositions and method of use |
US20040184995A1 (en) * | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
EP1755720A1 (de) * | 2004-05-20 | 2007-02-28 | Discovery Laboratories, Inc. | Verfahren, systeme und vorrichtungen für die nichtinvasive pulmonale abgabe |
EP1830810A4 (de) * | 2004-12-30 | 2011-02-02 | Dobeel Co Ltd | Sprühgetrocknete zusammensetzung mit proteinen der collectin-familie oder varianten davon und herstellungsverfahren dafür |
US8028697B2 (en) | 2005-04-28 | 2011-10-04 | Trudell Medical International | Ventilator circuit and method for the use thereof |
EP2009023A1 (de) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Neuartige Peptide und ihre Verwendung bei der Behandlung von Ödemen |
NZ588478A (en) * | 2008-03-17 | 2013-06-28 | Discovery Lab Inc | Ventilation circuit surrounding proximal aerosol delivery channel |
ES2402241T3 (es) | 2008-10-22 | 2013-04-30 | Trudell Medical International | Sistema de suministro de aerosol modular |
CA2754691C (en) * | 2009-03-26 | 2019-07-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
EP2711004A1 (de) * | 2009-10-05 | 2014-03-26 | Nutri-Fit GmbH & Co. KG | Verfahren zur Erhöhung der physikalischen Kapazität einer Säugetierunterkunft |
NZ630219A (en) | 2012-03-28 | 2016-09-30 | Discovery Lab Inc | Lyophilization of synthetic liposomal pulmonary surfactant |
AU2015226289B8 (en) | 2014-03-05 | 2019-10-31 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Device for providing a constant amount of aerosol |
CN106163600B (zh) | 2014-03-05 | 2019-03-22 | 弗劳恩霍夫应用研究促进协会 | 用于对气溶胶进行加湿的加湿器 |
KR102316762B1 (ko) * | 2014-03-18 | 2021-10-26 | 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 | 건조 분말 펩티드 약제 |
MX2020006634A (es) | 2017-12-21 | 2021-01-15 | Civitas Therapeutics Inc | Formulaciones de surfactantes para inhalacion. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58183621A (ja) * | 1982-04-22 | 1983-10-26 | Teijin Ltd | 肺表面活性物質を有効成分とする粉末剤の調製法 |
EP0119056A2 (de) * | 1983-03-10 | 1984-09-19 | Tokyo Tanabe Company Limited | Grenzflächenaktives Mittel und dieses enthaltende Arzneimittel zur Verwendung bei der Behandlung des Atemnotsyndroms |
EP0655237A1 (de) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3229179C2 (de) | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
US5260273A (en) | 1988-01-06 | 1993-11-09 | The Scripps Research Institute | Pulmonary surfactant protein and related polypeptide |
US5164369A (en) | 1988-01-06 | 1992-11-17 | The Scripps Research Institute | Pulmonary surfactant protein and related polypeptide |
DE69033745T2 (de) | 1989-07-11 | 2002-02-28 | Genentech Inc | Oberflächenaktive zusammensetzungen und verfahren |
IN172208B (de) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
ATE192930T1 (de) | 1990-10-17 | 2000-06-15 | Liposome Co Inc | Synthetische oberflächenaktive agentien auf der lunge |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
WO1995024183A1 (en) | 1994-03-07 | 1995-09-14 | Inhale Therapeutic Systems | Methods and compositions for pulmonary delivery of insulin |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
AU706195B2 (en) * | 1995-04-14 | 1999-06-10 | Inhale Therapeutic Systems | Powdered pharmaceutical formulations having improved dispersibility |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6077543A (en) * | 1996-12-31 | 2000-06-20 | Inhale Therapeutic Systems | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
ES2289823T3 (es) | 1998-08-25 | 2008-02-01 | Advanced Inhalation Research, Inc. | Formulaciones proteicas estables secadas por atomizacion. |
-
1997
- 1997-01-18 CA CA002244767A patent/CA2244767C/en not_active Expired - Lifetime
- 1997-01-18 EP EP97902186A patent/EP0877602B1/de not_active Expired - Lifetime
- 1997-01-18 KR KR10-1998-0705598A patent/KR100449789B1/ko not_active IP Right Cessation
- 1997-01-18 US US09/117,142 patent/US6315983B1/en not_active Expired - Lifetime
- 1997-01-18 WO PCT/EP1997/000230 patent/WO1997026863A1/de active IP Right Grant
- 1997-01-18 UA UA98084525A patent/UA59358C2/uk unknown
- 1997-01-18 PT PT97902186T patent/PT877602E/pt unknown
- 1997-01-18 TR TR1998/01408T patent/TR199801408T2/xx unknown
- 1997-01-18 AT AT97902186T patent/ATE212220T1/de active
- 1997-01-18 DE DE59706180T patent/DE59706180D1/de not_active Expired - Lifetime
- 1997-01-18 ES ES97902186T patent/ES2171883T3/es not_active Expired - Lifetime
- 1997-01-18 DK DK97902186T patent/DK0877602T3/da active
- 1997-01-18 JP JP52650697A patent/JP3725166B2/ja not_active Expired - Fee Related
- 1997-01-18 CZ CZ19982338A patent/CZ292186B6/cs not_active IP Right Cessation
-
2003
- 2003-06-24 CY CY0300048A patent/CY2366B1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58183621A (ja) * | 1982-04-22 | 1983-10-26 | Teijin Ltd | 肺表面活性物質を有効成分とする粉末剤の調製法 |
EP0119056A2 (de) * | 1983-03-10 | 1984-09-19 | Tokyo Tanabe Company Limited | Grenzflächenaktives Mittel und dieses enthaltende Arzneimittel zur Verwendung bei der Behandlung des Atemnotsyndroms |
EP0655237A1 (de) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 8349, Derwent World Patents Index; AN 83-835368, XP002010938 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0971698A1 (de) * | 1996-12-31 | 2000-01-19 | Inhale Therapeutic Systems | Aerolisiertes hydrophobisches medikament |
US8168223B1 (en) * | 1997-09-29 | 2012-05-01 | Novartis Pharma Ag | Engineered particles and methods of use |
US7790145B2 (en) | 1997-09-29 | 2010-09-07 | Novartis Ag | Respiratory dispersion for metered dose inhalers |
US9554993B2 (en) | 1997-09-29 | 2017-01-31 | Novartis Ag | Pulmonary delivery particles comprising an active agent |
WO2000010541A1 (en) * | 1998-08-25 | 2000-03-02 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
EP1767195A3 (de) * | 1998-08-25 | 2007-04-04 | Advanced Inhalation Research, Inc. | Stabile sprühgetrocknete Proteinformulierungen |
EP1767195A2 (de) * | 1998-08-25 | 2007-03-28 | Advanced Inhalation Research, Inc. | Stabile sprühgetrocknete Proteinformulierungen |
WO2000027360A1 (en) * | 1998-11-10 | 2000-05-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Treatment set containing lungsurfactant compositions |
WO2000076535A1 (en) * | 1999-06-11 | 2000-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
AU768299B2 (en) * | 1999-08-25 | 2003-12-04 | Alkermes, Inc. | Formulation for spray-drying large porous particles |
WO2001013892A3 (en) * | 1999-08-25 | 2001-06-21 | Advanced Inhalation Res Inc | Large porous particles by spray-drying |
WO2001013892A2 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Large porous particles by spray-drying |
US7053176B1 (en) | 1999-09-16 | 2006-05-30 | Altana Pharma Ag | Combination of C1-INH and lung surfactant for the treatment of respiratory disorders |
DE19957898A1 (de) * | 1999-12-01 | 2001-06-07 | Byk Gulden Lomberg Chem Fab | Neue Verwendung von Lungensurfactant |
US9439862B2 (en) | 2000-05-10 | 2016-09-13 | Novartis Ag | Phospholipid-based powders for drug delivery |
EP2851067A1 (de) | 2000-05-10 | 2015-03-25 | Novartis AG | Pulver auf Basis von Phospholipiden zur Arzneimittelverabreichung |
EP1280520B2 (de) † | 2000-05-10 | 2018-03-21 | Novartis AG | Pulver auf basis von phospholipiden zur wirkstoffverabreichung |
US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
US6982075B2 (en) | 2001-10-11 | 2006-01-03 | Altana Pharma Ag | Use of pulmonary surfactant |
US9421166B2 (en) | 2001-12-19 | 2016-08-23 | Novartis Ag | Pulmonary delivery of aminoglycoside |
WO2003077891A1 (fr) * | 2002-03-18 | 2003-09-25 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicales en poudre pour inhalation et procede de production de celles-ci |
US8236750B2 (en) | 2004-08-06 | 2012-08-07 | Nycomed Gmbh | Composition comprising a pulmonary surfactant and a TNF-derived peptide |
US8337815B2 (en) | 2004-12-23 | 2012-12-25 | Discovery Laboratories, Inc. | Pulmonary surfactant formulations |
US9289388B2 (en) | 2008-12-10 | 2016-03-22 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
US9693955B2 (en) | 2010-08-23 | 2017-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Humidified particles comprising a therapeutically active substance |
WO2017223502A1 (en) * | 2016-06-24 | 2017-12-28 | Civitas Therapeutics, Inc. | Surfactant formulations for inhalation |
AU2017281931B2 (en) * | 2016-06-24 | 2023-02-02 | Civitas Therapeutics, Inc. | Surfactant formulations for inhalation |
EP3727418A4 (de) * | 2017-12-21 | 2021-10-27 | Civitas Therapeutics, Inc. | Tensidformulierungen zur inhalation |
Also Published As
Publication number | Publication date |
---|---|
ATE212220T1 (de) | 2002-02-15 |
CY2366B1 (en) | 2004-06-04 |
EP0877602A1 (de) | 1998-11-18 |
CA2244767A1 (en) | 1997-07-31 |
DE59706180D1 (de) | 2002-03-14 |
DK0877602T3 (da) | 2002-05-06 |
JP2000503976A (ja) | 2000-04-04 |
US6315983B1 (en) | 2001-11-13 |
CA2244767C (en) | 2005-11-22 |
PT877602E (pt) | 2002-07-31 |
KR19990081886A (ko) | 1999-11-15 |
KR100449789B1 (ko) | 2005-02-03 |
CZ233898A3 (cs) | 1999-02-17 |
JP3725166B2 (ja) | 2005-12-07 |
ES2171883T3 (es) | 2002-09-16 |
TR199801408T2 (xx) | 1998-10-21 |
CZ292186B6 (cs) | 2003-08-13 |
EP0877602B1 (de) | 2002-01-23 |
UA59358C2 (uk) | 2003-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0877602B1 (de) | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen | |
DE69530792T2 (de) | Pharmazeutische zusammensetzung enthaltend proliposomen pulver zur inhalation | |
DE69834028T2 (de) | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. | |
DE69907951T2 (de) | Verbesserungen in bezug auf pulver | |
EP0736299B1 (de) | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung | |
DE69533128T2 (de) | Pharmazeutische akzeptabel dnase zusammensetzung | |
DE3008082A1 (de) | Carcinostatisches und die immunreaktion stimulierendes mittel, enthaltend lysophospholipid und phospholipid, und verfahren zur herstellung desselben | |
WO1996009831A2 (de) | Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten | |
DE69835594T2 (de) | Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten | |
DE3021006A1 (de) | Neues oberflaechenaktives material, verfahren zur herstellung desselben und dieses material enthaltendes pharmazeutisches mittel gegen hyalin-membran-erkrankung | |
DE60100500T2 (de) | Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen | |
DE69817774T2 (de) | Trägerstoff für trockenpulverinhalator, verfahren zu dessen herstellung und diesen enthaltende arzneimittel | |
DE60311798T2 (de) | Verbesserte mischungen synthetischer lipide zur herstellung einer rekonstituierten oberflächenaktiven substanz | |
DE69928279T2 (de) | Lungensurfactant zubereitungen enthaltendes behandlungset | |
EP0894094B1 (de) | Verfahren zur gewinnung eines komplexes aus wachstumsfaktoren | |
DE19602332A1 (de) | Verfahren zur Herstellung von pulverförmigen Lungensurfactant-Zubereitungen | |
WO1993015715A1 (de) | Asthma oder pulmonal-aerosolzubereitungen mit lecithin | |
EP2579862B1 (de) | Intranasale pharmazeutische zusammensetzung enthaltend olivenextrakt (hydroxytyrosol) und hopfenextrakt (xanthohumol) | |
DE1035319B (de) | Verfahren zur Herstellung eines vitaminhaltigen Pulvers | |
DE3018550C2 (de) | Verfahren zur umwandlung eines entzuendungshemmenden steroids in eine zur verabreichung mit aerosol geeignete form | |
EP0162129A1 (de) | Herstellung von Arznei- und Diätmittel aus Milch, Sahne oder Butterfett und deren Verwendung | |
DE69816093T2 (de) | Brausende mikrokugeln und verfahren zu ihrer herstellung | |
EP0470437A1 (de) | Wässriges Liposomensystem | |
DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
WO2006015841A1 (de) | Verfahren zur herstellung nicht klebender phospholipid-granulate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97193304.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BG BR CA CN CZ EE GE HU IL JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998/01408 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980705598 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2244767 Country of ref document: CA Ref document number: 2244767 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1998-2338 Country of ref document: CZ Ref document number: 09117142 Country of ref document: US Ref document number: PA/A/1998/006003 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997902186 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199800649 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1997902186 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-2338 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980705598 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997902186 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1998-2338 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980705598 Country of ref document: KR |